KYPROLIS — Total revenues
Products & Services · Total revenuesAmgen KYPROLIS — Total revenues remained flat by 0.0% to $353.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 6.1%, from $375.75M to $353.00M. Over 2 years (FY 2023 to FY 2025), KYPROLIS — Total revenues shows relatively stable performance with a 0.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand and successful clinical adoption for multiple myeloma treatment, while a decrease may signal increased competition from newer therapies or generic alternatives.
Detailed definition
This metric represents the total net sales generated from the Kyprolis product line, a proteasome inhibitor used in the...
Peer comparison
Comparable to oncology product revenue segments at other major biopharmaceutical firms, often benchmarked against competing multiple myeloma treatments.
amgn_segment_kyprolis_total_revenuesHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $1.40B | $1.50B | $1.41B |
| YoY Change | — | +7.1% | -6.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's kyprolis — total revenues?
- Amgen (AMGN) reported kyprolis — total revenues of $353.00M in Q4 2025.
- How has Amgen's kyprolis — total revenues changed year-over-year?
- Amgen's kyprolis — total revenues decreased by 6.1% year-over-year, from $375.75M to $353.00M.
- What is the long-term trend for Amgen's kyprolis — total revenues?
- Over 2 years (2023 to 2025), Amgen's kyprolis — total revenues has grown at a 0.3% compound annual growth rate (CAGR), from $1.40B to $1.41B.
- What does kyprolis — total revenues mean?
- The total revenue generated from sales of the Kyprolis oncology therapeutic.